Skip Navigation LinksHome > June 1, 2014 - Volume 28 - Issue 9 > HIV protease inhibitor exposure predicts cerebral small vess...
doi: 10.1097/QAD.0000000000000262
Clinical Science

HIV protease inhibitor exposure predicts cerebral small vessel disease

Soontornniyomkij, Virawudha,b; Umlauf, Anyaa; Chung, Sandra A.a; Cochran, Megan L.a; Soontornniyomkij, Benchawannab; Gouaux, Bena; Toperoff, Willa; Moore, David J.a,b; Masliah, Eliezera,c,d; Ellis, Ronald J.a,d; Grant, Igora,b; Achim, Cristian L.a,b,c

Collapse Box


Objective: HIV-associated neurocognitive disorders (HANDs) remain prevalent in patients who receive HAART and may be associated with cumulative exposure to antiretroviral medications and other factors. We proposed that chronic toxic effects of antiretroviral drugs could contribute to cerebral small vessel disease (CSVD), which might be one of the key underpinnings of HAND.

Design: Clinicopathological cross-sectional study of HIV-infected adults in the California NeuroAIDS Tissue Network.

Methods: We employed multivariable logistic regression methods to determine associations between HAART exposure (protease inhibitor-based, nonprotease inhibitor-based, or no HAART) and CSVD occurrence (standard histopathology: moderate/severe, mild, or absent). We also associated HAND (relative to normal cognition) with CSVD, HIV-related neuropathologic changes, older age at death (≥50 years), sex, or hepatitis C virus infection.

Results: We found that both mild and moderate/severe CSVD were associated with protease inhibitor-based HAART exposure after adjusting for diabetes mellitus [odds ratio (OR) 2.8 (95% confidence interval, CI 1.03–7.9) and 2.6 (95% CI 1.03–6.7), respectively, n = 134]. Moderate/severe CSVD was associated with diabetes after adjusting for HAART exposure [OR 7.4 (95% CI 1.6–70.7), n = 134]. Notably, HAND was associated with mild CSVD [OR 4.8 (95% CI 1.1–21.2), n = 63], which remained statistically significant after adjusting for vessel mineralization, HIV encephalitis, microglial nodular lesions, white matter lesions, or older age.

Conclusion: Protease inhibitor-based HAART exposure may increase the risk of CSVD and thereby neurocognitive impairment in HIV-infected adults. Apart from the possible direct toxicity to cerebral small vessels, protease inhibitor-based HAART may contribute indirectly to CSVD by inducing metabolic abnormalities.

© 2014 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.